Abstract
Purpose: To investigate whether multiphasic multidetector computed tomography (MDCT) enhancement can help identify the gain of chromosome 20 in clear cell renal cell carcinomas (RCCs), a rare prognostically significant cytogenetic abnormality. Methods: With the Institutional Review Board approval, we queried our institution’s pathology database to derive a cohort of 52 cases of clear cell RCC with preoperative four-phase renal mass protocol MDCT and karyotypes of the resected specimens during a 10-year period. Each lesion was evaluated for absolute and relative (compared to contralateral normal renal cortex) attenuations in each phase. Relative attenuation was calculated as [(lesion attenuation − cortex attenuation)/cortex attenuation] × 100. The absolute and relative attenuations were compared using t-tests. Results: Clear cell RCCs with the gain of 20 had significantly less nephrographic and excretory phase enhancement than clear cell RCCs without the gain of 20 (86.4 HU vs. 111.4 HU, p = 0.007; 70.0 HU vs. 89.4 HU, p = 0.003; respectively). Additionally, the relative nephrographic and excretory phase attenuations of clear cell RCCs with the gain of 20 were significantly less than that of clear cell RCCs without the gain of 20 (−52.7 vs. −34.7, p = 0.002; −44.9 vs. −31.1, p = 0.005; respectively). Conclusion: Multiphasic MDCT enhancement may assist in identifying the gain of chromosome 20 in clear cell RCCs, if validated in a large prospective trial.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2175-2181 |
| Number of pages | 7 |
| Journal | Abdominal Radiology |
| Volume | 41 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- Clear cell renal cell carcinoma
- Cytogenetics
- Multidetector computed tomography
- Renal cell carcinoma
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
- Gastroenterology
- Urology
Cite this
Clear cell renal cell carcinoma : identifying the gain of chromosome 20 on multiphasic MDCT. / Young, Jonathan R; Young, Jocelyn A.; Margolis, Daniel J.A.; Sauk, Steven; Pantuck, Allan J.; Sayre, James; Raman, Steven S.
In: Abdominal Radiology, Vol. 41, No. 11, 01.11.2016, p. 2175-2181.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clear cell renal cell carcinoma
T2 - identifying the gain of chromosome 20 on multiphasic MDCT
AU - Young, Jonathan R
AU - Young, Jocelyn A.
AU - Margolis, Daniel J.A.
AU - Sauk, Steven
AU - Pantuck, Allan J.
AU - Sayre, James
AU - Raman, Steven S.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Purpose: To investigate whether multiphasic multidetector computed tomography (MDCT) enhancement can help identify the gain of chromosome 20 in clear cell renal cell carcinomas (RCCs), a rare prognostically significant cytogenetic abnormality. Methods: With the Institutional Review Board approval, we queried our institution’s pathology database to derive a cohort of 52 cases of clear cell RCC with preoperative four-phase renal mass protocol MDCT and karyotypes of the resected specimens during a 10-year period. Each lesion was evaluated for absolute and relative (compared to contralateral normal renal cortex) attenuations in each phase. Relative attenuation was calculated as [(lesion attenuation − cortex attenuation)/cortex attenuation] × 100. The absolute and relative attenuations were compared using t-tests. Results: Clear cell RCCs with the gain of 20 had significantly less nephrographic and excretory phase enhancement than clear cell RCCs without the gain of 20 (86.4 HU vs. 111.4 HU, p = 0.007; 70.0 HU vs. 89.4 HU, p = 0.003; respectively). Additionally, the relative nephrographic and excretory phase attenuations of clear cell RCCs with the gain of 20 were significantly less than that of clear cell RCCs without the gain of 20 (−52.7 vs. −34.7, p = 0.002; −44.9 vs. −31.1, p = 0.005; respectively). Conclusion: Multiphasic MDCT enhancement may assist in identifying the gain of chromosome 20 in clear cell RCCs, if validated in a large prospective trial.
AB - Purpose: To investigate whether multiphasic multidetector computed tomography (MDCT) enhancement can help identify the gain of chromosome 20 in clear cell renal cell carcinomas (RCCs), a rare prognostically significant cytogenetic abnormality. Methods: With the Institutional Review Board approval, we queried our institution’s pathology database to derive a cohort of 52 cases of clear cell RCC with preoperative four-phase renal mass protocol MDCT and karyotypes of the resected specimens during a 10-year period. Each lesion was evaluated for absolute and relative (compared to contralateral normal renal cortex) attenuations in each phase. Relative attenuation was calculated as [(lesion attenuation − cortex attenuation)/cortex attenuation] × 100. The absolute and relative attenuations were compared using t-tests. Results: Clear cell RCCs with the gain of 20 had significantly less nephrographic and excretory phase enhancement than clear cell RCCs without the gain of 20 (86.4 HU vs. 111.4 HU, p = 0.007; 70.0 HU vs. 89.4 HU, p = 0.003; respectively). Additionally, the relative nephrographic and excretory phase attenuations of clear cell RCCs with the gain of 20 were significantly less than that of clear cell RCCs without the gain of 20 (−52.7 vs. −34.7, p = 0.002; −44.9 vs. −31.1, p = 0.005; respectively). Conclusion: Multiphasic MDCT enhancement may assist in identifying the gain of chromosome 20 in clear cell RCCs, if validated in a large prospective trial.
KW - Clear cell renal cell carcinoma
KW - Cytogenetics
KW - Multidetector computed tomography
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84975105754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975105754&partnerID=8YFLogxK
U2 - 10.1007/s00261-016-0813-9
DO - 10.1007/s00261-016-0813-9
M3 - Article
C2 - 27315079
AN - SCOPUS:84975105754
VL - 41
SP - 2175
EP - 2181
JO - Abdominal Radiology
JF - Abdominal Radiology
SN - 2366-004X
IS - 11
ER -